Loading...
Loading...
Browse all stories on DeepNewz
VisitPrimary reason cited for HHS extending COVID-19 vaccine liability protections by 2025?
Potential future pandemics • 25%
Vaccine manufacturer lobbying • 25%
Public health safety concerns • 25%
Other • 25%
Official statements or reports from HHS
HHS Extends COVID-19 Vaccine Liability Protections Through 2029, Following 40 Years of Immunity Under NCVIA
Dec 10, 2024, 04:58 PM
The U.S. Department of Health and Human Services (HHS) has announced an extension of liability protections for manufacturers and administrators of COVID-19 vaccines until 2029. This decision aims to safeguard against potential health emergencies in the future. Since the enactment of the National Childhood Vaccine Injury Act in 1986, vaccine manufacturers have had immunity from lawsuits related to vaccine injuries. Most routine vaccines have enjoyed similar protections for nearly 40 years, while vaccines developed for emergencies have had protections for 20 years. The extension of these protections has been largely uncontroversial, according to experts.
View original story
Public Health Concerns • 25%
Legal Challenges • 25%
Political Pressure • 25%
No Amendment • 25%
Safety concerns • 25%
Efficacy doubts • 25%
Ethical issues • 25%
Other • 25%
Safety concerns • 25%
Political pressure • 25%
Lack of demand • 25%
Other reasons • 25%
Legal challenges • 25%
Political pressure • 25%
Economic impact • 25%
Public opinion • 25%
Economic impact concerns • 25%
Political ideology • 25%
Public health strategy shift • 25%
Other reasons • 25%
Increased availability • 25%
Government incentives • 25%
Public health campaigns • 25%
Other • 25%
European Union • 25%
United Kingdom • 25%
Canada • 25%
No International Challenge • 25%
Safety concerns • 25%
Efficacy concerns • 25%
Public pressure • 25%
Other • 25%
Safety concerns • 25%
Personal freedom • 25%
Political strategy • 25%
Other reasons • 25%
Constitutional grounds • 25%
Economic impact • 25%
Public safety concerns • 25%
Other • 25%
Vaccine Safety Concerns • 25%
Lack of Access • 25%
Perceived Lack of Necessity • 25%
Other • 25%
Yes • 50%
No • 50%
European Union • 25%
Other • 25%
India • 25%
China • 25%